1
|
de Arriba MDC, Fernández G, Chacón-Solano E, Mataix M, Martínez-Santamaría L, Illera N, Carrión-Marchante R, Martín ME, Larcher F, González VM, Del Río M, Carretero M. FPR2 DNA Aptamers for Targeted Therapy of Wound Repair. J Invest Dermatol 2022; 142:2238-2248.e8. [PMID: 34979109 DOI: 10.1016/j.jid.2021.12.026] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Revised: 10/14/2021] [Accepted: 10/21/2021] [Indexed: 02/05/2023]
Abstract
Chronic wounds represent a major health problem worldwide. Some of the available therapies based on recombinant proteins usually fail owing to the hostile environment found at the wound bed. Aptamers appear as an attractive alternative to recombinant factors owing in part to their stability, sensitivity, specificity, and low-cost production. In this study, the Cell-Systematic Evolution of Ligands by EXponential Enrichment technology was employed to generate aptamers that specifically recognize and modulate the function of the FPR2, a receptor expressed in a variety of cells involved in wound repair. Three aptamers were obtained that specifically bound to FPR2 stable transfectants generated in HaCaT cells. The targeted aptamers were shown to act as FPR2 agonists in different in vitro functional assays, including wound healing assays, and elicited a similar pattern of response to that obtained with other known FPR2 peptide agonists, such as the human LL37 cathelicidin. We have also obtained in vivo evidence for the prohealing activities of one of these FPR2 aptamers in a skin-humanized mouse model developed by us, previously shown to accurately recreate the main phases of physiological human wound repair process. In conclusion, we provide evidence of the potential therapeutic value of FPR2 aptamers for cutaneous repair.
Collapse
Affiliation(s)
- María Del Carmen de Arriba
- Department of Bioengineering and Aerospace, University Carlos III of Madrid, Madrid, Spain; Centre for Biomedical Network Research on Rare Diseases (CIBERER), CB06/07/0019, ISCIII, Madrid, Spain; Biomedical Research Institute Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | | | - Esteban Chacón-Solano
- Department of Bioengineering and Aerospace, University Carlos III of Madrid, Madrid, Spain; Biomedical Research Institute Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Manuel Mataix
- Epithelial Biomedicine Division, Centre for Energy, Environment and Technology Research (CIEMAT), Madrid, Spain
| | - Lucía Martínez-Santamaría
- Department of Bioengineering and Aerospace, University Carlos III of Madrid, Madrid, Spain; Centre for Biomedical Network Research on Rare Diseases (CIBERER), CB06/07/0019, ISCIII, Madrid, Spain; Biomedical Research Institute Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Nuria Illera
- Biomedical Research Institute Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain; Epithelial Biomedicine Division, Centre for Energy, Environment and Technology Research (CIEMAT), Madrid, Spain
| | | | | | - Fernando Larcher
- Department of Bioengineering and Aerospace, University Carlos III of Madrid, Madrid, Spain; Centre for Biomedical Network Research on Rare Diseases (CIBERER), CB06/07/0019, ISCIII, Madrid, Spain; Biomedical Research Institute Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain; Epithelial Biomedicine Division, Centre for Energy, Environment and Technology Research (CIEMAT), Madrid, Spain
| | - Victor M González
- Aptus Biotech SL, Madrid, Spain; Aptamer Group, IRYCIS-Hospital Ramón y Cajal, Madrid, Spain
| | - Marcela Del Río
- Department of Bioengineering and Aerospace, University Carlos III of Madrid, Madrid, Spain; Centre for Biomedical Network Research on Rare Diseases (CIBERER), CB06/07/0019, ISCIII, Madrid, Spain; Biomedical Research Institute Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Marta Carretero
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), CB06/07/0019, ISCIII, Madrid, Spain; Biomedical Research Institute Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain; Epithelial Biomedicine Division, Centre for Energy, Environment and Technology Research (CIEMAT), Madrid, Spain.
| |
Collapse
|